Cormedix Drug Patent Portfolio
Cormedix owns 1 orange book drug protected by 4 US patents Given below is the list of Cormedix's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11738120 | Synthesis of taurolidine, purity profiles and polymorphs | 15 Apr, 2042 | Active |
| US7696182 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin | 16 May, 2025 | Active |
| US8541393 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin | 02 Nov, 2024 | Active |
| US9339036 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin | 02 Nov, 2024 | Active |
Latest Legal Activities on Cormedix's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cormedix.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Application under 35 USC 156 Filed | 08 Jan, 2024 | US7696182 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 04 Oct, 2023 | US9339036 |
| Recordation of Patent eGrant | 29 Aug, 2023 | US11738120 |
| Mail Patent eGrant Notification | 29 Aug, 2023 | US11738120 |
|
Email Notification
Critical
| 29 Aug, 2023 | US11738120 |
|
Recordation of Patent Grant Mailed
Critical
| 29 Aug, 2023 | US11738120 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 29 Aug, 2023 | US11738120 |
| Patent eGrant Notification | 29 Aug, 2023 | US11738120 |
|
Email Notification
Critical
| 10 Aug, 2023 | US11738120 |
|
Electronic Review
Critical
| 10 Aug, 2023 | US11738120 |
|
Issue Notification Mailed
Critical
| 09 Aug, 2023 | US11738120 |
|
Application Is Considered Ready for Issue
Critical
| 02 Aug, 2023 | US11738120 |
| Dispatch to FDC | 02 Aug, 2023 | US11738120 |
| Printer Rush- No mailing | 21 Jul, 2023 | US11738120 |
|
Pubs Case Remand to TC
Critical
| 18 Jul, 2023 | US11738120 |
Cormedix's Family Patents
Cormedix Drug List
Given below is the complete list of Cormedix's drugs and the patents protecting them.
1. Defencath
Defencath is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11738120 | Synthesis of taurolidine, purity profiles and polymorphs |
15 Apr, 2042
(17 years from now)
| Active |
| US7696182 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
16 May, 2025
(7 months from now)
| Active |
| US8541393 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
02 Nov, 2024
(23 days from now)
| Active |
| US9339036 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
02 Nov, 2024
(23 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Defencath's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List